Project leader: Nicolo TONALI
For diagnosis and therapy - (22/09/2023)
The research on new strategies for earlier diagnosis is among the most active areas in Alzheimer’s science. The hope is to diagnose the disease in an early stage before irreversible brain damage or mental decline has occurred. There are currently no validated pre-symptomatic biomarkers for AD, but researchers are investigating several promising candidates, including brain imaging, proteins in CSF, blood and urine, and genetic risk profiling. While it has been already shown that there is a poor correlation between amyloid plaques and cognitive decline, the diagnostic role of early and soluble aggregative forms such as oligomers, appearing earlier than the plaques, has not yet been fully investigated.
This project aims to provide novel fluorescent peptides to detect early biomarkers of amyloid pathologies with the aim of developing clinical and research tools to facilitate early and reliable diagnosis of amyloid-related diseases. The project focuses primarily on the amyloid β peptide, implicated in Alzheimer’s disease, and aims to extend the approach used to other amyloidogenic proteins, implicated in other pathologies.
Contact : Nicolo TONALI – BioCIS, Faculty of pharmacy, Paris-Saclay University
